公开(公告)号：US6051605A

公开(公告)日：2000-04-18

申请号：US240949

申请日：1999-01-29

Applicant: Thomas Capiris ,  David Thomas Connor ,  Steven Robert Miller ,  Paul Charles Unangst ,  Lawrence David Wise

Inventor： Thomas Capiris ,  David Thomas Connor ,  Steven Robert Miller ,  Paul Charles Unangst ,  Lawrence David Wise

IPC: A61K31/09 ,  A61K31/10 ,  A01N37/38

CPC classification number: A61K31/10 ,  A61K31/09

Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, and to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors.

Abstract translation: 本发明涉及作为多巴胺D4受体的拮抗剂的化合物，以及使用作为多巴胺D4受体拮抗剂的化合物治疗精神病和精神分裂症的方法。

公开(公告)号：US06794402B2

公开(公告)日：2004-09-21

申请号：US10276054

申请日：2002-11-12

Applicant: Sham Shridhar Nikam ,  Ian Leslie Scott ,  Brian Alan Sherer ,  Lawrence David Wise

Inventor： Sham Shridhar Nikam ,  Ian Leslie Scott ,  Brian Alan Sherer ,  Lawrence David Wise

IPC: A61K31423

CPC classification number: C07D263/58 ,  C07D235/26 ,  C07D277/68 ,  C07D413/12 ,  C07D417/12

Abstract: Described are bicycle-substituted cyclohexylamines of Formula I and their pharmaceutically acceptable salts thereof: The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease. The substituents are defined in the specification.

Abstract translation: 描述了式I的自行车取代的环己胺及其药学上可接受的盐：该化合物是可用于治疗脑血管病症例如脑缺血，心脏停搏，中风和帕金森病的NMDA受体通道复合物的拮抗剂。 取代基在说明书中定义。

公开(公告)号：US06765022B2

公开(公告)日：2004-07-20

申请号：US10297055

申请日：2002-12-02

Applicant: Russell Joseph Deorazio ,  Sham Shridhar Nikam ,  Ian Leslie Scott ,  Brian Alan Sherer ,  Lawrence David Wise

Inventor： Russell Joseph Deorazio ,  Sham Shridhar Nikam ,  Ian Leslie Scott ,  Brian Alan Sherer ,  Lawrence David Wise

IPC: A61K31137

CPC classification number: C07C215/60 ,  C07C215/52 ,  C07C215/54 ,  C07C2601/14

Abstract: Described are cyclobexylamine derivatives of Formula I, Formula II, or Formula III and their pharmaceutically acceptable salts thereof: The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease. The substituents are described in the specification.

Abstract translation: 描述了式I，式II或式III的环丁胺衍生物及其药学上可接受的盐：该化合物是可用于治疗脑血管病症的NMDA受体通道复合物的拮抗剂，例如脑缺血，心脏骤停，中风， 和帕金森病。 取代基在说明书中描述。

公开(公告)号：US5945421A

公开(公告)日：1999-08-31

申请号：US909171

申请日：1997-08-11

Applicant: Thomas Richard Belliotti ,  Clifton John Blankley ,  Suzanne Ross Kesten ,  Lawrence David Wise ,  David Juergen Wustrow

Inventor： Thomas Richard Belliotti ,  Clifton John Blankley ,  Suzanne Ross Kesten ,  Lawrence David Wise ,  David Juergen Wustrow

IPC: C07D215/12 ,  A61K31/495 ,  A61K31/47 ,  C07D401/06 ,  C07D403/06

CPC classification number: C07D215/12

Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors, and to pharmaceutically acceptable compositions that contain a dopamine D4 receptor antagonist.

Abstract translation: 本发明涉及作为多巴胺D4受体的拮抗剂的化合物，使用作为多巴胺D4受体的拮抗剂的化合物治疗精神病和精神分裂症的方法以及含有多巴胺D4受体拮抗剂的药学上可接受的组合物。

公开(公告)号：US06683101B2

公开(公告)日：2004-01-27

申请号：US10297263

申请日：2002-12-03

Applicant: Russell Joseph Deorazio ,  Sham Shridhar Nikam ,  Ian Leslie Scott ,  Brian Alan Sherer ,  Lawrence David Wise

Inventor： Russell Joseph Deorazio ,  Sham Shridhar Nikam ,  Ian Leslie Scott ,  Brian Alan Sherer ,  Lawrence David Wise

IPC: A61K314184

CPC classification number: C07D263/58 ,  C07D235/26

Abstract: Described are heterocycle-substituted cyclohexylamines of formula (I), and their pharmaceutically acceptable salts thereof. The compounds of the formula (I) are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease,

Abstract translation: 描述了式（I）的杂环取代的环己胺及其药学上可接受的盐。 式（I）的化合物是可用于治疗脑血管病症例如脑缺血，心脏骤停，中风和帕金森病的NMDA受体通道复合物的拮抗剂，

公开(公告)号：US06642398B2

公开(公告)日：2003-11-04

申请号：US10324929

申请日：2002-12-20

Applicant: Thomas Richard Belliotti ,  Justin Stephen Bryans ,  Ihoezo Victor Ekhato ,  Augustine Tobi Osuma ,  Robert Michael Schelkun ,  Jacob Bradley Schwarz ,  Andrew John Thorpe ,  Lawrence David Wise ,  David Juergen Wustrow ,  Po-Wai Yuen

Inventor： Thomas Richard Belliotti ,  Justin Stephen Bryans ,  Ihoezo Victor Ekhato ,  Augustine Tobi Osuma ,  Robert Michael Schelkun ,  Jacob Bradley Schwarz ,  Andrew John Thorpe ,  Lawrence David Wise ,  David Juergen Wustrow ,  Po-Wai Yuen

IPC: C07D1000

CPC classification number: C07C229/32 ,  C07B2200/07 ,  C07C229/08 ,  C07C229/20 ,  C07C229/22 ,  C07C229/30 ,  C07C229/34 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14

Abstract: The instant invention is a series of novel mono- and disubstituted 3-propyl gamma aminobutyric acids of Formula I The compounds are useful as therapeutic agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, arthritis, sleep disorders, IBS, and gastric damage. Methods of preparing the compounds and useful intermediates are also part of the invention.

Abstract translation: 本发明是一系列新型的单取代和二取代的3-丙基γ-氨基丁酸，其化合物可用作治疗癫痫，微弱发作，运动功能减退，颅内疾病，神经变性障碍，抑郁症，焦虑症，恐慌症， 疼痛，神经病理学障碍，关节炎，睡眠障碍，IBS和胃损伤。 制备化合物和有用的中间体的方法也是本发明的一部分。

公开(公告)号：US5760050A

公开(公告)日：1998-06-02

申请号：US807517

申请日：1997-02-27

Applicant: David Thomas Connor ,  Steven Robert Miller ,  Paul Charles Unangst ,  Lawrence David Wise

Inventor： David Thomas Connor ,  Steven Robert Miller ,  Paul Charles Unangst ,  Lawrence David Wise

IPC: A61K31/436 ,  A61K31/444 ,  A61K31/4709 ,  C07D491/04 ,  C07D491/052 ,  A61K31/44

CPC classification number: C07D491/04 ,  A61K31/436 ,  A61K31/444 ,  A61K31/4709

Abstract: 1,2,3,4-Tetrahydro-chromeno�3,4-c!pyridin-5-ones of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.5 include hydrogen, alkyl, alkoxy, hydroxy, halo, nitro, amino, and trifluoromethyl; R.sub.4 is unsubstituted or substituted phenyl, pyridyl, or quinolinyl; and n is 0 to 4, are useful to treat psychosis in mammals, particularly schizophrenia.

Abstract translation: 其中R1，R2，R3和R5包括氢，烷基，烷氧基，羟基，卤素，硝基的1,2,3,4-四氢 - 色烯并[3,4-c]吡啶-5-酮 ，氨基和三氟甲基; R4是未取代或取代的苯基，吡啶基或喹啉基; 并且n为0至4，可用于治疗哺乳动物，特别是精神分裂症中的精神病。

公开(公告)号：US06187808B1

公开(公告)日：2001-02-13

申请号：US09402046

申请日：1999-09-27

Applicant: Stephen Joseph Johnson ,  Leonard Theodore Meltzer ,  Lawrence David Wise

Inventor： Stephen Joseph Johnson ,  Leonard Theodore Meltzer ,  Lawrence David Wise

IPC: A61K3115

CPC classification number: C07C251/84 ,  C07C251/44 ,  C07C2602/10

Abstract: This invention provides 6-amino-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one oximes and hydrazones which are useful in treating Parkinson's disease.

Abstract translation: 本发明提供可用于治疗帕金森病的6-氨基-3,4,5,6,7,8-六氢-2H-萘-1-酮肟和腙。

公开(公告)号：US5922719A

公开(公告)日：1999-07-13

申请号：US909170

申请日：1997-08-11

Applicant: Stephen Joseph Johnson ,  Suzanne Ross Kesten ,  Lawrence David Wise ,  David Juergen Wustrow

Inventor： Stephen Joseph Johnson ,  Suzanne Ross Kesten ,  Lawrence David Wise ,  David Juergen Wustrow

IPC: A61K31/496 ,  A61K31/506 ,  C07D405/12 ,  A61K31/495 ,  A61K31/505 ,  C07D239/32 ,  C07D241/20

CPC classification number: A61K31/496 ,  A61K31/506 ,  C07D405/12

Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors, and to pharmaceutically acceptable compositions that contain a dopamine D4 receptor antagonist.

Abstract translation: 本发明涉及作为多巴胺D4受体的拮抗剂的化合物，使用作为多巴胺D4受体的拮抗剂的化合物治疗精神病和精神分裂症的方法以及含有多巴胺D4受体拮抗剂的药学上可接受的组合物。

公开(公告)号：US5916914A

公开(公告)日：1999-06-29

申请号：US907680

申请日：1997-08-08

Applicant: David Thomas Connor ,  Stephen Joseph Johnson ,  Suzanne Ross Kesten ,  Steven Robert Miller ,  Paul Charles Unangst ,  Lawrence David Wise

Inventor： David Thomas Connor ,  Stephen Joseph Johnson ,  Suzanne Ross Kesten ,  Steven Robert Miller ,  Paul Charles Unangst ,  Lawrence David Wise

IPC: C07D311/14 ,  C07D311/16 ,  A61K31/35 ,  C07D311/02 ,  C07D319/12

CPC classification number: C07D311/16 ,  C07D311/14

Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, and to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors.